Regulatory Approval
Concord Biotech Receives USFDA ANDA Approval for Mycophenolate Mofetil Oral Suspension USP, 200 mg/mL
NSE
concordbio
BSE
543960
Concord Biotech has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (USFDA) for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL. The approval strengthens the company’s U.S. product portfolio and provides access to an estimated US$30 million market opportunity.
PRICE-SENSITIVE TRIGGER
Event: USFDA ANDA Approval Received
Type: Regulatory Approval
Impact: Positive
Immediate Effect: The company can commercialize Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL in the U.S. market, expanding its product portfolio and enhancing growth opportunities in regulated international markets.
Key Metrics:
- Product Approved: Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL
- Regulatory Authority: U.S. Food and Drug Administration (USFDA)
- Market Opportunity: Approximately US$30 million
- Approval Type: Abbreviated New Drug Application (ANDA)
- Target Market: United States
Highlight:
- Concord Biotech has secured USFDA approval for a product addressing an estimated US$30 million U.S. market opportunity.
What Happened ?
Concord Biotech announced that it has received USFDA approval for its ANDA covering Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.
Mycophenolate mofetil is an antimetabolite immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric recipients aged three months and above undergoing kidney, heart, or liver transplantation, when used in combination with other immunosuppressants.
The approval enables Concord Biotech to enter a niche transplant-care segment in the U.S. pharmaceutical market and further strengthens its regulated-market product portfolio.
Key Details
USFDA Approval for Mycophenolate Mofetil Oral Suspension:
- Approval received from the U.S. Food and Drug Administration (USFDA).
- Product approved: Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.
- Approval granted under the ANDA pathway.
- Product is used for prevention of organ rejection in transplant patients.
- Applicable for kidney, heart and liver transplant recipients.
- Can be prescribed to adult and pediatric patients aged three months and older.
- Estimated U.S. market size for the product is approximately US$30 million.
- Approval expands Concord Biotech’s regulated-market product portfolio.
- Supports the company’s long-term growth strategy across international markets.
Note:
- The approval adds another regulated-market product to Concord Biotech’s portfolio and enhances its presence in specialized immunosuppressant therapies used in transplant care.
Risk Analysis
Summary:
- While regulatory approval removes a key entry barrier, commercial success will depend on market penetration, competition from generic manufacturers, pricing dynamics, and supply-chain execution in the U.S. market.
Key Risks:
- Competitive generic landscape may affect market share.
- Pricing pressure can impact profitability.
- Commercial launch execution remains critical.
- Regulatory compliance requirements remain ongoing.
- Market opportunity realization depends on customer acquisition and distribution capabilities.
Worst Case Scenario:
- If pricing pressure intensifies or market penetration remains limited, the commercial contribution from the approved product could be lower than anticipated despite regulatory clearance.
Risk Level: Medium
Company Commentary
- USFDA has approved Concord Biotech’s ANDA for Mycophenolate Mofetil for Oral Suspension USP, 200 mg/mL.
- The approval aligns with the company’s growth strategy.
- The product approval strengthens Concord Biotech’s position in the U.S. pharmaceutical market.
- The approval enhances the company’s product offerings in regulated markets.
- Management believes the approval supports long-term growth across U.S. and international markets.
Official Exchange Filing: Concord Biotech Limited